The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer

Nature Communications

Volumn 5, Issue , 2014, Pages

  Chakravarty, Dimple ^a   Sboner, Andrea ^a   Nair, Sujit S ^b   Giannopoulou, Eugenia ^c,d   Li, Ruohan ^e   Hennig, Sven ^f   Mosquera, Juan Miguel ^a   Pauwels, Jonathan ^a   Park, Kyung ^a   Kossai, Myriam ^a   Macdonald, Theresa Y ^a   Fontugne, Jacqueline ^a   Erho, Nicholas ^g   Vergara, Ismael A ^g   Ghadessi, Mercedeh ^g   Davicioni, Elai ^g   Jenkins, Robert B ^h   Palanisamy, Nallasivam ^i,j   Chen, Zhengming ^a   Nakagawa, Shinichi ^k   Hirose, Tetsuro ^l   Bander, Neil H ^a   Beltran, Himisha ^a   Fox, Archa H ^e   Elemento, Olivier ^a   Rubin, Mark A ^a   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c NEW YORK CITY COLLEGE OF TECHNOLOGY   (United States)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

^g Research and Development   (Canada)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^j HENRY FORD HEALTH SYSTEM   (United States)

^k RIKEN   (Japan)

^l HOKKAIDO UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ANDROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; LONG UNTRANSLATED RNA; MESSENGER RNA; NUCLEAR ENRICHED ABUNDANT TRANSCRIPT 1; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRANSCRIPTOME; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA, HUMAN; NEAT1 LONG NON-CODING RNA, HUMAN;

ANDROGEN; CANCER; ESTROGENIC COMPOUND; GENE EXPRESSION; MENS HEALTH; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; RNA SEQUENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION; ADENOCARCINOMA; DISEASE COURSE; GENETIC EPIGENESIS; GENETICS; METABOLISM; PROSTATE TUMOR; SEQUENCE ANALYSIS; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DISEASE PROGRESSION; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR ALPHA; HUMANS; MALE; PROSTATIC NEOPLASMS; RNA, LONG NONCODING; SEQUENCE ANALYSIS, RNA;

EID: 84923284989     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6383     Document Type: Article

References (58)

1. Heinlein, C. A. & Chang, C. Androgen receptor in prostate cancer. Endocr. Rev. 25, 276-308 (2004).
2. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. New Engl. J. Med. 364, 1995-2005 (2011).
3. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl. J. Med. 367, 1187-1197 (2012).
4. Ricke, W. A. et al. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J. 22, 1512-1520 (2008).
5. Clemson, C. M. et al. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol. Cell 33, 717-726 (2009).
6. Rhodes, D. R. et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9, 166-180 (2007).
7. Arredouani, M. S. et al. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin. Cancer Res. 15, 5794-5802 (2009).
8. Barwick, B. G. et al. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br. J. Cancer 102, 570-576 (2010).
9. Best, C. J. et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin. Cancer Res. 11, 6823-6834 (2005).
10. Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M. & Gerald, W. L. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113, 913-923 (2004).
11. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
12. Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811-816 (2004).
13. LaTulippe, E. et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62, 4499-4506 (2002).
14. Liu, P. et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res. 66, 4011-4019 (2006).
15. Luo, J. et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 61, 4683-4688 (2001).
16. Singh, D. et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203-209 (2002).
17. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
18. Tomlins, S. A. et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39, 41-51 (2007).
19. Vanaja, D. K., Cheville, J. C., Iturria, S. J. & Young, C. Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 63, 3877-3882 (2003).
20. Varambally, S. et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406 (2005).
21. Wallace, T. A. et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 68, 927-936 (2008).
22. Yu, Y. P. et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22, 2790-2799 (2004).
23. Lin, C. Y. et al. Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol. 5, R66 (2004).
24. Romano, A. et al. Identification of novel ER-alpha target genes in breast cancer cells: gene- and cell-selective co-regulator recruitment at target promoters determines the response to 17beta-estradiol and tamoxifen. Mol. Cell. Endocrinol. 314, 90-100 (2010).
25. Yu, J. et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454 (2010).
26. Giannopoulou, E. G. & Elemento, O. An integrated ChIP-seq analysis platform with customizable workflows. BMC Bioinformatics 12, 277 (2011).
27. Bond, C. S. & Fox, A. H. Paraspeckles: nuclear bodies built on long noncoding RNA. J. Cell Biol. 186, 637-644 (2009).
28. Holzbeierlein, J. et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164, 217-227 (2004).
29. Magee, J. A. et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 61, 5692-5696 (2001).
30. Tamura, K. et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 67, 5117-5125 (2007).
31. Welsh, J. B. et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61, 5974-5978 (2001).
32. Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
33. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
34. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
35. Erho, N. et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE 8, e66855 (2013).
36. Karnes, R. J. et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J. Urol. 190, 2047-2053 (2013).
37. Rickman, D. S. et al. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 12, 1031-1040 (2010).
38. Nakagawa, S., Naganuma, T., Shioi, G. & Hirose, T. Paraspeckles are subpopulation-specific nuclear bodies that are not essential in mice. J. Cell Biol. 193, 31-39 (2011).
39. Guttman, M. et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458, 223-227 (2009).
40. Burger, M. J. et al. Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int. J. Cancer 100, 228-237 (2002).
41. Gumulec, J. et al. Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers. Neoplasma 59, 191-201 (2012).
42. Jiang, N., Zhu, S., Chen, J., Niu, Y. & Zhou, L. A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants. PLoS ONE 8, e74386 (2013).
43. Ross, J. S. et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res. 9, 6357-6362 (2003).
44. Xiao, Z. et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 61, 6029-6033 (2001).
45. Chu, C., Quinn, J. & Chang, H. Y. Chromatin isolation by RNA purification (ChIRP). J. Vis. Exp. 61, pii: 3912 (2012).
46. Bernstein, E. & Allis, C. D. RNA meets chromatin. Genes Dev. 19, 1635-1655 (2005).
47. Khalil, A. M. et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl Acad. Sci. USA 106, 11667-11672 (2009).
48. Tsai, M. C. et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 329, 689-693 (2010).
49. Wang, K. C. et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 472, 120-124 (2011).
50. Bonkhoff, H., Fixemer, T., Hunsicker, I. & Remberger, K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am. J. Pathol. 155, 641-647 (1999).
51. Setlur, S. R. et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J. Natl Cancer Inst. 100, 815-825 (2008).
52. Singh, P. B., Matanhelia, S. S. & Martin, F. L. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur. J. Cancer 44, 928-936 (2008).
53. Nicolaiew, N. et al. Association between estrogen and androgen receptor genes and prostate cancer risk. Eur. J. Endocrinol. 160, 101-106 (2009).
54. Gibb, E. A. et al. Human cancer long non-coding RNA transcriptomes. PLoS ONE 6, e25915 (2011).
55. Amaral, P. P., Clark, M. B., Gascoigne, D. K., Dinger, M. E. & Mattick, J. S. lncRNAdb: a reference database for long noncoding RNAs. Nucleic Acids Res. 39, D146-D151 (2011).
56. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B (Methodol.) 57, 289-300 (1995).
57. Rhodes, D. R. et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6 (2004).
58. Blute, M. L., Bergstralh, E. J., Iocca, A., Scherer, B. & Zincke, H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol. 165, 119-125 (2001).